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Abstract
A better understanding of how T1 vaccination confers immunity would facilitate the rational design of improved vaccines
against contagious bovine pleuropneumonia (CBPP). We show here that mycoplasmas-induced recall proliferation and IFN-c
responses are detected in cattle that received multiple shots of T1 vaccines. These anamnestic responses were under the
strict control of CD4+ T lymphocytes. Moreover, CD62L expression indicated that both CD4+ effector memory (Tem) and
central memory (Tcm) T lymphocytes are elicited in these animals. Comparative analysis with data from cattle that
completely recovered from CBPP infection revealed similar anamnestic T-cell responses albeit at a lower magnitude for T1-
vaccinated animals, particularly in the Tcm compartment. In conclusion, we discuss how our current understanding of T-cell
responses will contribute to ongoing efforts for the improvement of future CBPP vaccines.
Citation: Totte P, Yaya A, Sery A, Wesonga H, Wade A, et al. (2013) Characterization of Anamnestic T-cell Responses Induced by Conventional Vaccines against
Contagious Bovine Pleuropneumonia. PLoS ONE 8(2): e57509. doi:10.1371/journal.pone.0057509
Editor: Odir A. Dellagostin, Federal University of Pelotas, Brazil
Received January 7, 2013; Accepted January 23, 2013; Published February 28, 2013
Copyright:  2013 Totte et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded in parts by grants from the European Union, under the supervision of OAU/IBAR (Kenya), and from the Australian aid program.
J.N. was sponsored by a CSIRO-AUSaid grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: philippe.totte@cirad.fr
Introduction
Improved vaccines are needed to control the spread of
contagious bovine pleuropneumonia (CBPP), a devastating re-
spiratory disease of cattle caused by Mycoplasma mycoides subsp.
mycoides biotype Small Colony (MmmSC), and a substantial
economic burden for sub-Sahara Africa [1,2,3]. Indeed, the only
vaccines currently in use are live vaccines, derived from the T1
strain and empirically attenuated through serial passage in
embryonated eggs before production in artificial growth media
[4]. Unfortunately these vaccines possess variable efficacy, induce
short-lived immunity necessitating costly annual booster immuni-
zations, and still retain some virulence causing sometimes adverse
reactions at inoculation sites [5,6]. Although some technical
advances were accomplished in quality control and storage, recent
efforts to address the limited efficacy of CBPP vaccines by
increasing vaccine dosage and formulation resulted in little success
[2,7].
Comprehensive information on the nature of immunity induced
by T1 vaccines will help improve their efficacy. Also, it may lead to
the definition of predictors of vaccine efficacy that will allow
a simple and rapid screening approach of novel vaccine
formulations before fastidious and costly clinical trials in
ruminants. As far as T1 vaccines are concerned, and apart from
one report by Roberts et al in 1973 [8], research on immune
responses triggered by vaccination has focused exclusively on
humoral immunity. These studies indicate that antibody responses
elicited by T1 vaccines are generally low and short-lived, and,
thus, not appropriate to assess the immune status of animals or to
serve as predictors of vaccine success [5,9]. Preliminary work on
cell-mediated immunity (CMI) failed to detect sensitization of
lymphocytes in vaccinated animals but the methods used were of
low sensitivity and specificity [8].
Here, we have analyzed T-cell immune responses induced by
T1 vaccines using highly sensitive methods such as enzyme-linked
immunospot (ELISPOT) for the detection of MmmSC-specific
IFN-c production, and carboxyfluorescein diacetate succinimidyl
ester (CFSE) to measure lymphocytes proliferation. The two
currently approved vaccines, namely, T1/44 and its streptomycin-
resistant derivate, T1sr, were used in this study. In addition, single
immunization was compared to multiple annual booster immuni-
zation known to improve overall herd immunity. Also, we
investigated the induction of both effector memory (Tem) and
central memory (Tcm) T cells given their importance in
maintaining long-term protective immunity [10]. Finally, a com-
parative analysis was performed between data from the present
study and our knowledge of CMI induced in animals that
recovered from CBPP.
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Materials and Methods
1. Ethics Statement
The African research institutions involved in the animal
experiments did not have ethic committees operational at the
time of the study. However, each received authorization to
conduct the study from their respective ministry/government
department namely the Ministry of livestock Development in
Kenya, the Ministry of Livestock and Fisheries in Mali and the
Ministry of Livestock, Fisheries and Animal Husbandry in
Cameroon. In addition, all experiments were carried out
according to the guidelines in the guide to the Care and Use of
Experimental Animals provided by the French Ministry of
Agriculture.
2. Animals and Vaccinations
Naı¨ve zebu cattle above 3 years of age were purchased from
CBPP-free areas in each country and were confirmed negative for
antibodies to MmmSC by ELISA. Animals were dewormed and
treated against ticks when needed. They were confined in
a paddock or a brick house, where they were fed on hay, water
and mineral supplements. Vaccinations were performed as follow:
i) at KARI in Kenya: animals received a single subcutaneous
injection of a T1/44 vaccine batch; ii) at CVL in Mali, animals
received two intramuscular injections at one month interval of
a T1-SR vaccine batch; iii) at LANAVET in Cameroon, animals
previously vaccinated twice on a yearly basis were purchased from
a region were annual CBPP vaccination takes place under
LANAVET’s supervision. At LANAVET, these animals received
a third subcutaneous injection of a T1/44 vaccine batch. All
vaccines preparations were quality controlled by the pan African
veterinary vaccine centre (PANVAC) in Ethiopia and used at
a dosage of 107 viable mycoplasmas per injection [2]. Control
nonvaccinated animals received PBS only and were kept with the
vaccinated animals.
3. Proliferation Assays and Flow Cytometry
PBMC were isolated from peripheral blood as described
previously [11] one month after the last vaccination and stored
at 280uC in cryotubes containing 2–56107cells/ml in fetal calf
serum supplemented with 10% DMSO until shipment to CIRAD
under liquid nitrogen. Upon thawing, PBMC were loaded with
CFSE (Invitrogen, France) at a final concentration of 1 mM before
incubation for 9 days with 5 mg/ml of heat-inactivated MmmSC
(strain T1/44) or 2.5 mg/ml of the mitogen Concanavalin A
(ConA) as a positive control and as described before [12].
Phenotype analysis of PBMC was performed as described
previously with minor modifications [11,12]. Briefly, cells were
harvested and surface stained with the following primary mono-
clonal antibodies (mAb): mAb IL-A11 (IgG2a) for CD4, mAb
BAQ92A (IgG1) for CD62L, mAb GC6A (IgM) for CD45R and
mAb GC42A1 (IgG1) for CD45RO (all obtained from VMRD,
Pullman, WA). Cells were then washed and stained with a cocktail
of fluorochrome-conjugated, isotype-specific antibodies (Tebu,
France). Debris and dead cells were excluded from analysis based
on size and inclusion of 7-amino-actinomycin D (7-AAD) as
a viability dye. Four-color analyses were performed with
a FACScanto flow cytometer equipped with the FACSDiva TM
software (BD Biosciences) after the acquisition of at least 5,000
events. Control isotype antibodies were used to evaluate non-
specific binding and to set gates and quadrants delineating positive
populations. Proliferation levels are expressed as percentages of
CFSElow cells which correspond to decreased CFSE fluorescence
intensities relative to that in undivided cells. They measure the
cumulated proliferation since day 0 irrespective of the number of
division cycles.
4. IFN-c Assays
The BovigamTM ELISA (Prionics AG, Switzerland) was used to
assess IFN-c production in 5-days old supernatants of PBMC
cultured as above. Briefly, supernatants were collected after
centrifugation and stored at 220uC until assayed according to the
manufacturer’s instructions; results are expressed as mean O.D.
values of duplicates.
The bovine IFN-c ELISpotplus kit (Mabtech, Sweden) was used
to establish the numbers of ex vivo antigen-responding cells in
cultured PBMC and following the manufacturer’s instructions.
Briefly, the assay was carried out in duplicates in polyvinylidene
fluoride (PVDF) 96-well plates coated with a capture mAb specific
for bovine IFN-c. PBMC (26105/well) resuspended in RPMI-
1640 supplemented with 10% FCS (Eurobio), 2 mM glutamine,
antibiotics and 2-mercaptoethanol (Sigma) were stimulated with
the same antigens as in the proliferation assay and incubated for
20 h at 37uC in a humidified atmosphere with 5% CO2. After
extensive washing, the plates were incubated with a detection mAb
against bovine IFN-c. Finally, IFN-c secreting cells or spots were
stained using a combination of alkaline phosphatase (ALP), 5-
Bromo-4-chloro-3-indolyl phosphate (BCIP) and nitroblue tetra-
zolium (NBT). Spot forming cells (SFC) were enumerated using an
automated ELISPOT reader (Biosys, Germany). Results are
presented as the mean number of MmmSC-specific IFN-c-spot
forming cells/106 PBMC.
5. Depletion Studies
Cells were depleted of CD4+ T cells by positive selection using
a magnetic activated cell sorting system (Macs, Miltenyi Biotec,
France) as previously described (12). Briefly, cells were stained with
mAb ILA11 (IgG2a) against bovine CD4 (VMRD, USA) and
incubated with Macs microbeads conjugated to goat anti-mouse
IgG (H+L) prior to separation on MS columns and according to
the manufacturer’s instructions. Unbound cell fractions collected
from the columns repeatedly contained less than 5% CD4+ T cells
as confirmed by flow cytometry.
6. Statistics
A nonparametric Mann-Whitney U-test (http://elegans.som.
vcu.edu/˜leon/stats/) was used to analyze differences between
vaccinated and nonvaccinated animals. A difference was consid-
ered to be significant at a P value of ,0.05.
Results
1. Anamnestic Cellular Responses are Detected in Cattle
that Received Multiple Shots of T1 Vaccines
At individual levels, MmmSC-specific recall proliferation in
vaccinated cattle could only be detected in animals that received
three shots of T1 vaccines (Fig. 1). However, at group levels, these
vaccinated cattle could not be discriminated from nonvaccinated
animals when recall proliferation of total PBMC was assessed
(Fig. 1a). It is only when proliferation among CD4+ T lymphocytes
was measured that significantly (P=0.03) higher responses were
detected in the vaccinated group versus the nonvaccinated group
(Fig. 1b).
MmmSC-induced recall IFN-c responses in vaccinated animals
were also detected at substantial levels only in animals receiving
multiple vaccine injections (Fig. 2). At group levels, both ELISA
(P=0.028) and ELISPOT (P=0.016) methods allowed discrimi-
nation between vaccinated and nonvaccinated animals (Fig. 2a&b).
T-Cell Responses to CBPP Vaccines
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Recall proliferative and IFN-c responses to the mitogen ConA
were comparable for all groups irrespective of the vaccination
status and number of vaccine shots (see Fig. S1).
2. Anamnestic Cellular Responses Induced by T1 Vaccines
are under the Strict Control of CD4+ T cells
In vaccinated animals showing the strongest T-cell responses,
MmmSC-induced recall proliferation was evident among cells that
did not belong to the CD4 sub-type although to a lesser extent
than in the CD4+ population. Given the potential inhibitory
properties of CD4+ T lymphocytes (i.e., Tregulatory or Treg) it
was of interest to analyse immune responses occuring in their
absence. Therefore, depletion studies were performed and clearly
indicated that both proliferation and IFN-c production induced by
MmmSC Ags required the presence of CD4+ T lymphocytes
(Fig. 3).
3. Both CD4+ Tem and Tcm are Elicited by T1 Vaccines
We have shown previously that expression of CD62L among
proliferating CD4+ T lymphocytes could discriminate between
Tem and Tcm in MmmSC presensitized animals [13]. Here, we
have assessed the contribution of both populations in anamnestic
T-cell responses of vaccinated cattle, focusing on animals that
responded above nonvaccinated animals (i.e., 4 out of 5), to
concentrate on vaccine-induced T-cell responses. We found that
viable CD4+ T lymphocytes actively proliferating in response to
MmmSC comprised both CD62L+ and CD62L2 populations
(Fig. 4). In general, the percentage of CD62L+ cells slightly
exceeded the percentage of CD62L2 cells among proliferating
CD4+ T lymphocytes (Table 1) whereas in non stimulated CD4
the ratio was 4565%.
Analysis of activation/memory markers indicated strong
upregulation of CD45RO and down regulation of CD45R surface
expression by proliferating CD4+ T lymphocytes (Fig. 5). It can be
observed from Fig. 5 that, among proliferating CD4, the majority
of CD62L2 and CD62L+ also followed that same expression
pattern (i.e., upregulation of CD45RO and downregulation of
CD45R) which is indicative of a memory phenoytpe.
Discussion
The paucity of data on the immunogenicity of T1 vaccines
against CBPP, and more specifically on CMI, has prompted this
study. Our goal is to improve our understanding of protective
immunity and facilitate the design of more effective CBPP
vaccines that are urgently needed. Three African countries took
part in the study to account for differences in national veterinary
Figure 1. MmmSC-induced recall proliferative responses of
pbmc (a), and CD4+ T cells (b), collected from nonvaccinated
(open circles) and vaccinated (closed circles) animals (n=5)
one month after single, double and triple vaccine inoculations.
Results represent the net effect of MmmSC stimulation (i.e., stimulated
cultures minus non-stimulated cultures) and are representative of 2
independent experiments. Bars indicate median values and asterisks
represent significant difference between vaccinated and naı¨ve groups.
doi:10.1371/journal.pone.0057509.g001
Figure 2. MmmSC-induced recall IFN-c responses measured by
ELISA (a) and ELISPOT (b) using pbmc collected from
nonvaccinated (open circles) and vaccinated (closed circles)
animals (n =5) one month after single, double and triple
vaccine inoculations. Results represent the net effect of MmmSC (i.e.,
stimulated cultures minus non-stimulated cultures) and are represen-
tative of two experiments. Bars indicate median values and asterisks
represent significant difference between vaccinated and naı¨ve groups.
doi:10.1371/journal.pone.0057509.g002
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specificities and practices. This also allowed comparison of
different vaccine strains and vaccination regimens.
In the first place, recall proliferation and IFN-c production by
PBMC, two markers of CMI, were chosen to assess the presence of
anamnestic T-cell responses in vaccinated animals. Significant
MmmSC-induced recall proliferation and IFN-c responses, both at
individual and group levels, were detected exclusively in cattle that
received three shots of T1 vaccines. These results confirm pioneer
studies by Roberts and colleagues indicating that no recall
activation of lymphocytes could be detected in cattle vaccinated
two months previously in the tail tip with a single dose of the T1
vaccine [8]. A booster immunization one month later had little
effect as shown in the present study. A possible explanation is that
live T1 vaccines induce apoptosis in lymphocytes as has been
shown in vitro for the T1/44 strain [14]. In our study, there was no
obvious signs left of apoptosis in PBMC as indicated by
uncompromised responses to the mitogen ConA (see Figure S1).
Additional longitudinal studies are needed to fully explore the
possibility that transient CMI is induced by a single shot of T1
vaccines.
Further characterization of CMI elicited by multiple shots of T1
vaccines underlined the determinant role of CD4+ T lymphocytes
in recall MmmSC-induced proliferation and IFN-c responses.
Although the contribution of other T-cell sub-types cannot be
excluded, MmmSC-induced responses in vitro were under the strict
control of CD4+ T lymphocytes as shown by depletion studies.
Moreover, CD4+ T-cell responders elicited by multiple injections
of T1 vaccines comprised both Tem- and Tcm-like sub-types as
suggested by CD62L surface expression. Interestingly, a pre-
dominant role for CD4+ T lymphocytes in CMI, including both
Tem and Tcm, has also been reported for cattle that fully
recovered from CBPP [13]. Full recovery from clinical disease is
known to induce life-long protective immunity against CBPP
[15,16]. However, although qualitatively comparable, the magni-
tude of CMI was lower in T1-vaccinated cattle versus recovered
cattle as indicated by several parameters (Table 1 and ref 13): 1) 2/
5 v/s 10/10 animals had more than 50% of CFSElow cells among
CD4+ T cells after in vitro stimulation; 2) 2/5 v/s 10/10 animals
showed an increase in total CD4+ T cells among stimulated
PBMC; 3) 0/5 v/s 10/10 animals showed above 70% CD62L+
cells among proliferating CD4+ T cells which is a marker for Tcm
in our model [13]. This is consistent with the short-lived immunity
afforded by T1 vaccines observed in the field which justifies costly
annual booster immunizations campaigns [16].
Although not a final proof, this study further supports the idea
that both CD4+ Tem and Tcm play a role in protective immunity
Figure 3. Effect of CD4 depletion on MmmSC-induced recall proliferation (a) and IFN-c (b) responses of pbmc collected from
vaccinated animals. Cells were incubated in the absence (NoAg) or presence of MmmSC Ags (MmmSC), or in the presence of the mitogen
Concanavalin A (ConA) as a positive control. Results are expressed as mean percentages (6 standard deviation) from three animals.
doi:10.1371/journal.pone.0057509.g003
Table 1. Effect of in vitro MmmSC stimulation on CD4+ T lymphocytes collected from cbpp-vaccinated cattle.
Animal
number
% CD4+ T cells in
cultures stimulateda with: % proliferationb among CD4+ T cells
% CD62L+ cells among proliferating
CD4+ T cells
NoAg MmmSC NoAg MmmSC
1 21.563 3464 762 60614 6264
2 24.565 23.567 463 37612 6062
3 1562 1861 662 2566 5161
4 2065 4064 362 51614 6165
apbmc were loaded with CFSE and incubated for 9 days with inactivated MmmSC before cell surface staining and analysis by flow cytometry as described in
material&methods. Results are expressed as mean (+/2 SD) percentages of 2 experiments.
bPercentages of CFSElow cells within the gated CD4+ population.
doi:10.1371/journal.pone.0057509.t001
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since booster immunizations are associated with increased pro-
tection rate of T1 vaccines [17]. There is however a need for
studies on CMI taking place in vaccinated/recovered cattle
undergoing CBPP challenge to confirm the role of CD4+ T cells
in protection. Moreover, the contribution of functionally different
CD4+ effectors or Tem (i.e., Th1, Th2, Th17, Treg, polyfunc-
tional CD4) will have to be clarified to understand the mechanisms
underlying protective immunity [18]. This is especially true since
severe CBPP may be associated with excessive cytokine production
[19] and, thus, inappropriate immunization may exacerbate
disease rather than protect. Additionally, this will allow identifi-
cation of suitable correlates of protection that would facilitate
future vaccine evaluation in cattle. Another important aspect of
vaccine efficacy is long-term immunity particularly for CBPP to
avoid expensive annual booster immunizations. Tcm mediate
long-term immunity and have been associated with protection
against chronic diseases [10, 20, 21, and 22], Moreover, in bovine
tuberculosis, Tcm responses are detected long after Tem responses
have waned and they are good correlates of vaccine-induced
protection [23,24].
Altogether, these results suggest that the immunogenicity of T1
vaccines is poor but that it can be increased by several booster
Figure 4. Both CD62L+CD4+ and CD62L2CD4+ T cells proliferate in response to MmmSC stimulation in vitro. Results of a typical four-
color flow cytometric analysis are shown for one vaccinated animal. Cells were loaded with CFSE and incubated for 9 days with inactivated MmmSC
before cell surface staining and analysis by flow cytometry as follows: (a) a first gate (P1) was used to exclude dead cells (7AAD+) and cell debris
(FSC,50); (b) a second gate (P2) was set, among P1 gated cells, to delineate viable and proliferating CD4+ T cells (CFSElow or CFSE,16103); and (c),
histograms were opened on gate P2 to obtain the percentage of CD62L+ cells among proliferating CD4+ T cells (i.e., P3).
doi:10.1371/journal.pone.0057509.g004
Figure 5. Cell surface expression of CD62L (a), and CD45RO (b), and CD45R (c) markers by proliferating (R1 gate) and non-
proliferationg (R2 gate) CD4+ T cells stimulated with MmmSC Ags. Percentages of positive cells within gated populations are shown on
histograms.
doi:10.1371/journal.pone.0057509.g005
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immunizations. In that case, animals developed CMI that was
qualitatively comparable to animals that have fully recovered from
CBPP infections. However, quantitative analysis suggests that
there is room for substantial increase in CMI, particularly in the
Tcm compartment, even after three shots of T1 vaccines. This
warrants further work to assess new boosting strategies other than
homologous booster immunization. Our results also further
support the idea that protection against CBPP is somehow
associated with CD4+ Tem, the precise phenotype of which
remains to be elucidated, as well as CD4+ Tcm. Therefore,
markers of these responses have potential as predictors of vaccine
efficacy and deserve further evaluation in future CBPP challenge
studies.
Supporting Information
Figure S1 Recall responses to the mitogen ConA measured by: i)
proliferation among CD4+ T lymphocytes (a), ii) IFN-c production
measured by ELISA (b) and ELISPOT (c). Cells were collected
from nonvaccinated (open circles) and vaccinated (closed circles)
animals (n = 5) one month after single, double and triple vaccine
inoculations. Results represent the net effect of ConA (i.e.,
stimulated cultures minus non-stimulated cultures).
(TIF)
Acknowledgments
We express our appreciation to the staff of national veterinary institutes for
excellent technical help and their dedication to the welfare of test animals.
We are very grateful to V. Rodrigues for technical help with flow
cytometry.
Author Contributions
Reviewed critically the manuscript: AY MN JN AW FT. Conceived and
designed the experiments: PT AY HW AS MN FT. Performed the
experiments: PT AS AW HB JN. Analyzed the data: PT FT. Wrote the
paper: PT.
References
1. Tambo NE, Maina WO, Ndi C (2006) An estimation of the economic impact of
contagious bovine pleuropneumonia in Africa. Rev Sci Tech Oie 3: 999–1011.
2. Thiaucourt F, Aboubakar Y, Wesonga H, Manso-Silvan L, Blanchard A (2004)
Contagious bovine pleuropneumonia vaccines and control strategies: recent
data. In: Control of Infectious Animal Diseases by Vaccination, A. Schudel and M.
Lombard, Editors, Karger:Basel. p. 99–111.
3. (2006) In:4th FAO-OIE-AU/IBAR-IAEA. Consultative Group Meeting on
CBPP in Africa. Rome: FAO.
4. Sheriff D, Piercy SE (1952) Experiments with an avianised strain of the organism
of contagious bovine pleuropneumonia. Vet Rec 64: 615–621.
5. Thiaucourt F, Yaya A, Wesonga H, Hubschle OJ, Tulasne JJ, et al. (2000)
Contagious bovine pleuropneumonia. A reassessment of the efficacy of vaccines
used in Africa. Ann. N Y Acad Sci 916: 71–80.
6. Revell SG (1973) Local reactions following contagious bovine pleuropneumonia
vaccination in Zambia, Trop Anim Health Prod 5: 246–252.
7. Nkando I, Ndinda J, Kuria J, Naessens J, Mbithi F, et al. (2012) Efficacy of two
vaccine formulations against contagious bovine pleuropneumonia (CBPP) in
Kenyan indigenous cattle. Res Vet Sci 2: 568.
8. Roberts DH, Windsor RS, Masiga WN, Kariavu CG (1973) Cell-mediated
immune response in cattle to Mycoplasma mycoides var. mycoides, Infect
Immun 8: 349–354.
9. Hamsten C, Neiman M, Schwenk JM, Hamsten M, March JB, et al. (2009)
Recombinant surface proteomics as a tool to analyze humoral immune responses
in bovines infected by Mycoplasma mycoides subsp. mycoides small colony type.
Mol Cell Proteomics 11: 2544–54.
10. Zaph C, Uzonna J, Beverley SM, Scott P (2004) Central memory T cells mediate
long-term immunity to Leishmania major in the absence of persistent parasites.
Nat Med 10: 1104.
11. Dedieu L, Balcer-Rodrigues V, Yaya A, Hamadou B, Cisse O, et al. (2005)
Gamma interferon-producing CD4 T-cells correlate with resistance to
Mycoplasma mycoides subsp. Mycoides S.C. infection in cattle. Vet Immunol
Immunopathol 107: 217–233.
12. Totte´ P, Rodrigues V, Yaya A, Hamadou B, Cisse O, et al. (2008) Analysis of
cellular responses to Mycoplasma mycoides subsp. mycoides small colony
biotype associated with control of contagious bovine pleuropneumonia. Vet Res
39: 1–11.
13. Totte´ P, Duperray C, Dedieu L (2010) CD62L defines a subset of pathogen-
specific bovine CD4 with central memory cell characteristics. Dev Comp
Immunol 34: 177–82.
14. Dedieu L, Chapey E, Balcer-Rodrigues V (2005) Mycoplasma mycoides ssp.
mycoides biotype small colony-secreted components induce apoptotic cell death
in bovine leucocytes. Scand J Immunol 6: 528–38.
15. Hudson JR (1968) Contagious bovine pleuropneumonia. The keeping properties
of the V5 vaccine used in Austtralia. Aust Vet J 44: 123–9.
16. Masiga WN, Domenech J, Windsor RS (1996) Manifestation and epidemiology
of contagious bovine pleuropneumonia in Africa. Rev Sci Tech 18: 59–65.
17. Wesonga HO, Thiaucourt F (2000) Experimental Studies on the Efficacy of T1sr
and T1/44 Vaccine Strains of Mycoplasma mycoides Subspecies mycoides
(Small Colony) against a Field Isolate Causing Contagious Bovine Pleuropneu-
monia in Kenya - Effect of a Revaccination. Rev Elev Med Vet Pays Trop 4:
313–318.
18. Seder RA, Darrah PA, Roederer M (2008) T-cell quality in memory and
protection: implications for vaccine design. Nat Rev Immunol 8: 247–258.
19. Sacchini F, Luciani M, Salini R, Scacchia M, Pini A (2012) Plasma levels of
TNF-a, IFN-c, IL-4 and IL-10 during a course of experimental contagious
bovine pleuropneumonia. BMC Vet Res 8: 44.
20. Keating SM, Bejon P, Berthoud T, Vuola JM, Todryk S, et al. (2005) Durable
human memory T cells quantifiable by cultured enzyme-linked immunospot
assays are induced by heterologous prime boost immunization and correlate with
protection against malaria. J Immunol 175: 5675–80.
21. Soloff AC, Liu X, Gao W, Day RD, Gambotto A, et al. (2009) Adenovirus 5-
and 35-based immunotherapy enhances the strength but not breadth or quality
of immunity during chronic SIV infection. Eur J Immunol 9: 2437–49.
22. Goletti D, Butera O, Bizzoni F, Casetti R, Girardi E, et al. (2006) Region of
difference 1 antigen-specific CD4+ memory T cells correlate with a favorable
outcome of tuberculosis. J Infect Dis 7: 984–92.
23. Whelan AO, Wright DC, Chambers MA, Singh M, Hewinson RG, et al. (2008)
Evidence for enhanced central memory priming by live Mycobacterium bovis
BCG vaccine in comparison with killed BCG formulations. Vaccine 2: 166–73.
24. Hope JC, Thom ML, McAulay M, Mead E, Vordermeier HM, et al. (2011)
Identification of surrogates and correlates of protection in protective immunity
against Mycobacterium bovis infection induced in neonatal calves by vaccination
with M. bovis BCG Pasteur and M. bovis BCG Danish. Clin Vaccine Immunol
3: 373–9.
T-Cell Responses to CBPP Vaccines
PLOS ONE | www.plosone.org 6 February 2013 | Volume 8 | Issue 2 | e57509
